<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02248207</url>
  </required_header>
  <id_info>
    <org_study_id>248.527</org_study_id>
    <nct_id>NCT02248207</nct_id>
  </id_info>
  <brief_title>Tolerability of Sifrol® in Ambulatory Patients Suffering From Parkinson's Disease</brief_title>
  <official_title>Management of Parkinson's Disease Patients at Their First Visits in a Neurological Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to obtain information about the co-operation of the different physician-colleagues in
      the treatment of patients with Parkinson's disease, both in private practices and clinics and
      about the primary treatment strategies in the pharmacotherapy of Parkinson's disease and to
      collect data on the tolerability of Sifrol® in ambulatory patients suffering from Parkinson's
      disease under routing conditions
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <primary_completion_date type="Actual">November 2003</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Global Assessment of efficacy by investigator on a 4-point scale</measure>
    <time_frame>after 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in actual Parkinson symptoms</measure>
    <time_frame>Baseline, after 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Global Assessment of tolerability by investigator on a 4-point scale</measure>
    <time_frame>after 8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse drug reactions</measure>
    <time_frame>up to 8 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1293</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Parkinson Disease patients</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pramipexole</intervention_name>
    <arm_group_label>Parkinson Disease patients</arm_group_label>
    <other_name>Sifrol®</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Parkinson's disease recruited at specialist neurologist (private practices
        and clinics)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with Parkinson's disease who present to the specialist neurologist practice
             for the first time without or with referral and who are planned to receive or either
             be switched to Sifrol or continue the previously prescribed therapy with Sifrol® can
             be included in this observational study

        Exclusion Criteria:

          -  Neurologists are asked to consider the Summary of Product Characteristics (SPC) for
             Sifrol®
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2014</study_first_submitted>
  <study_first_submitted_qc>September 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2014</study_first_posted>
  <last_update_submitted>September 22, 2014</last_update_submitted>
  <last_update_submitted_qc>September 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pramipexole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

